证券日报网讯 2月27日，天智航发布公告称，公司2025年实现营业收入28325.76万元，同比增长 58.38%；归属于母公司所有者的净利润亏损18403.18万元，亏损同比扩大51.93%。 （文章来源：证券日报） ...

证券日报网讯 2月27日，奥泰生物发布公告称，公司2025年度实现营业总收入91130.05万元，同比增长 5.16%；归属于母公司所有者的净利润为21828.01万元。 （文章来源：证券日报） ...

Core Insights - The company reported a revenue of 1.648 billion yuan for the year 2025, marking a year-on-year growth of 13.04%, with a net profit attributable to shareholders of 198 million yuan and a net profit excluding non-recurring items of 165 million yuan, driven by the deep implementation of its "integrated diagnosis and treatment" strategy [2] Group 1: Strategic Developments - In 2025, the company expanded its "integrated diagnosis and treatment" strategy, moving from the diagnostic field to treatment and from the domestic market to global markets [3] - The acquisition of Zhongshan Haiji (now known as "Sangshang Haiji") marked a key milestone in entering the health consumption sector, with plans for clinical trials for a new indication of its growth hormone injection product [3] - The company strengthened its industry influence in grassroots medical testing and upstream genetic technology through investments in various firms, enhancing its competitive edge in high-barrier segments like blood molecular diagnostics [3] Group 2: Ecosystem and Capital Initiatives - The company actively built an ecosystem of partnerships with industry leaders such as BeiGene and Alibaba Health, creating a full lifecycle service loop from screening to health management [4] - To support its integrated strategy, the company established the Hunan Jin Furong Sangshang Biological Industry Fund, focusing on AI medical applications and innovative drugs, with an initial fundraising of 820 million yuan [4] Group 3: Innovation and R&D - The company increased its R&D investment to approximately 310 million yuan, accounting for nearly 20% of its revenue, and introduced multiple innovative products in key areas such as respiratory diseases and genetic sequencing [5] - The launch of the SUREXEVO series, the world's first AI-integrated molecular POCT product, highlights the company's commitment to integrating AI across various medical applications [6] - The company achieved significant deployment of integrated machines, with over 200 units installed, and established a complete product matrix in genetic sequencing, enhancing its "instrument + reagent + data" integration [6] Group 4: Future Outlook - The chairman emphasized the need to seize the second growth opportunity in the industry by innovating new products and solutions, integrating AI deeply into all business processes, and transforming technical solutions into commercially viable products [7]

（文章来源：证券日报） 证券日报网讯 2月27日，爱博医疗发布公告称，公司2025年度实现营业总收入148270.27万元，同比增长 5.15%；归属于母公司所有者的净利润26541.48万元。 ...

证券日报网讯 2月27日，普门科技发布公告称，公司2025年度实现营业总收入103783.10万元，实现归属 于母公司所有者的净利润18609.47万元。 （文章来源：证券日报） ...

（文章来源：证券日报） 证券日报网讯 2月27日，硕世生物发布公告称，公司2025年实现营业总收入34038.04万元，同比下降 2.64%；归属于母公司所有者的净利润为-3971.03万元，同比亏损扩大3770.86万元。 ...

（文章来源：证券日报） 证券日报网讯 2月27日，辰光医疗发布2025年年度业绩快报公告称，公司2025年实现营业收入为 89939697.09元，同比下降24.42%，归属于上市公司股东的净利润预计为-60736016.14元。 ...

（文章来源：证券日报） 证券日报网讯 2月27日，亚辉龙发布2025年度业绩快报公告称，公司2025年度实现营业总收入180910.78 万元，同比下降10.07%；归属于上市公司股东的净利润2401.90万元，同比下降92.03%。 ...

报告期内，公司核心产品凭借有显著临床价值的差异化创新，在满足过往未被完全满足的重要临床需求 方面，持续获得国内外专家的广泛认可，产品已进入全球超过60个国家和地区，在超过2,000家医院实 现临床应用。其中，海外业务营业收入同比增长超过130%，在公司收入占比进一步提升，公司国际化 业务取得快速突破。 智通财经APP讯， 北芯生命(688712.SH)发布2025年度业绩快报，报告期内，公司实现营业收入 54,210.81万元，较上年同期增长71.23%;归属于母公司所有者的净利润8,062.19万元，归属于母公司所有 者的扣除非经常性损益的净利润6,513.95万元，较上年同期实现扭亏为盈。 ...

智通财经APP讯， 北芯生命(688712.SH)发布2025年度业绩快报，报告期内，公司实现营业收入 54,210.81万元，较上年同期增长71.23%;归属于母公司所有者的净利润8,062.19万元，归属于母公司所有 者的扣除非经常性损益的净利润6,513.95万元，较上年同期实现扭亏为盈。 报告期内，公司核心产品凭借有显著临床价值的差异化创新，在满足过往未被完全满足的重要临床需求 方面，持续获得国内外专家的广泛认可，产品已进入全球超过60个国家和地区，在超过2,000家医院实 现临床应用。其中，海外业务营业收入同比增长超过130%，在公司收入占比进一步提升，公司国际化 业务取得快速突破。 ...